Shares of Pfizer (PFE) have been steadily trending lower in recent weeks. The company has its hands in many pies with intriguing drugs that can help power sales growth for many years to come. However, the depressed valuation seems to imply that Pfizer will hit a growth funk once the COVID-19 pandemic winds down. After Pfizer's latest earnings result, the stock is trading at a mere 9.5 times trailing earnings — well below the pharma industry average of nearly 23 times. Going into a recession or slowdown, biopharma stocks should be in high demand.
https://www.tipranks.com/news/article/pfizer-stock-way-too-cheap-to-ignore-despite-recent-headwinds?utm_source=advfn.com&utm_medium=referral
Pfizer (NYSE:PFE)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Pfizer Charts.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Pfizer Charts.